Combination therapy for treating cancer
AssigneeIsm Biosciences LLC
InventorsMax Temnik, Victor Gurin, Sergey Gurin
Life of this patent
Estimating the term…
Abstract
A method of treating cancer or cancer metastasis comprising administering to a patient in need thereof a therapeutically effective amount of one or more anticancer agent selected from the group consisting of chemotherapy, an immunotherapy, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass.
Claims10
A method of treating a primary melanoma cancer with a combination therapy comprising administering to a patient in need thereof:
- (i) a therapeutically effective amount of one or more anticancer agents selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and
- (ii) a therapeutically effective amount of at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass;
- wherein said anti-cancer agent(s) are known to be effective against primary melanoma cancer.
A method of treating a metastatic melanoma cancer with a combination therapy comprising administering to a patient in need thereof:
- (i) a therapeutically effective amount of one or more anti-cancer agents selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and
- (ii) a therapeutically effective amount of at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass;
- wherein said anti-cancer agent(s) are known to be effective against said metastatic melanoma cancer.
Dependencies are inferred from the claim text.